Strategy and business model

We focus on researching, developing and marketing innovative medicines that have the potential to transform the lives of people around the world with rare and other specialized conditions.

Download the PDF

Where we are heading

Transforming lives

Our purpose is to enable people with life altering conditions to lead better lives.

A leading global biotech

We aspire to be a leading, global biotech delivering innovative medicines to patients with rare diseases and other specialty conditions.

10 x 20

To guide and motivate us on our journey we seek to achieve product sales of $10 billion by 2020.

Product sales; Percent CAGR

2013: five billion dollars in-line. 2020: Seven billion dollars in-line, three billion dolalrs existing pipline, ten billion-plus dollars upside.
* $5bn represents sales from continuing operations.

10 x 20 Details

  • In-line: $7 billion expected from on-market products1
  • Pipeline: $3 billion expected from existing pipeline1
  • Upside: NPS Pharma, Lumena, Fibrotech, BIKAM, Cinryze new uses, early stage pipeline and future Business Development provide additional upside to 10 x 20
  • 1 Shire announced its 10 x 20 aspiration on June 23, 2014 and seeks to achieve 2020 product sales of $10 billion from its In-line and Pipeline portfolio as at May 2014.

How we are going to get there

Four strategic drivers

To realize our aspiration to become a leading biotech, we will concentrate our efforts on four strategic drivers:

Our business model

To drive our growth, we have a unified, global business model focused on our strategic drivers. We lead our business through our Executive Committee which, supported by our In-line and Pipeline Committees, ensures we allocate resources and make decisions across the enterprise in the best interests of all our stakeholders – patients, employees, physicians, payers, policy makers and investors.

This streamlined way of working means we can quickly adapt and change our business around the world as we pursue and make the most of opportunities to develop and market innovative treatments that have the potential to transform the lives of people around the world.

In-line − commercial excellence

Our In-line focus is on marketing products to meet the needs of patients today.

Pipeline − innovation excellence

Our Pipeline focus is on the products we are developing to meet the needs of patients tomorrow.

One culture

We have a clear and strong patient-focused, performance-based culture which is grounded in our purpose of enabling people with life altering conditions to lead better lives:

  • We have the courage to lead the way
  • We are agile and adaptable to meet the changing needs of our stakeholders
  • We deliver on our promises to all of our stakeholders
  • We fearlessly innovate to address unmet patient need
  • We do the right thing, in the right way

We value and invest in our employees to ensure they have the capabilities and support to implement our strategy, achieve our vision and deliver value to all our stakeholders.